scholarly journals Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

2014 ◽  
Vol 176 (3) ◽  
pp. 320-326 ◽  
Author(s):  
T. Koudriavtseva ◽  
E. Sbardella ◽  
E. Trento ◽  
V. Bordignon ◽  
G. D'Agosto ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Lymphocyte Subsets ◽  
Peripheral Lymphocyte ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

2018 ◽  
Vol 394 ◽  
pp. 127-131 ◽  
Author(s):  
Brian C. Healy ◽  
Bonnie I. Glanz ◽  
Jonathan D. Zurawski ◽  
Maria Mazzola ◽  
Tanuja Chitnis ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Cognitive Functioning in Multiple Sclerosis

1969 ◽  
Vol 115 (524) ◽  
pp. 765-775 ◽  
Author(s):  
K. L. Jambor
Keyword(s):  
Multiple Sclerosis ◽  
Direct Method ◽  
Cross Sectional Study ◽  
Control Group ◽  
Cross Sectional ◽  
Short Period ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

In previous studies the estimation of the incidence of intellectual changes in multiple sclerosis has varied from as low as 2 per cent. (Cottrell and Wilson, 1926) to as high as 72 per cent. (Ombredane, 1929). In order to establish the incidence accurately, the most satisfactory method would clearly be a long-term follow-up (covering lifetime) of a sample of multiple sclerosis patients. Any cross-sectional study would include patients in varying degrees of advancement of the disease, and patients found to be free of intellectual deficits at the time of investigation would not necessarily remain so. Also, the indirect psychometric assessment of intellectual loss is notoriously difficult, and the direct method of follow-up would give much more accurate results. The only direct study up to date has been that of Canter (1951), who found a highly significant (i.e. 13·48 points) loss on re-testing multiple sclerosis patients on the Army General Classification Test after a four-year period. Even after such a short period as six months he found slight losses on most Wechsler-Bellevue subtests, in contrast to an average gain of six full IQ points of the control group.

scholarly journals Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

2018 ◽  
Vol 9 ◽  
Author(s):  
Maxi Kaufmann ◽  
Rocco Haase ◽  
Undine Proschmann ◽  
Tjalf Ziemssen ◽  
Katja Akgün
Keyword(s):  
Multiple Sclerosis ◽  
Real World ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

scholarly journals Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

2021 ◽  
pp. 135245852110002
Author(s):  
Bruce AC Cree ◽  
Jeffrey A Cohen ◽  
Anthony T Reder ◽  
Davorka Tomic ◽  
Diego Silva ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Therapeutic Benefit ◽  
Disease Modifying Therapies ◽  
Long Term Follow Up ◽  
Post Hoc ◽  
Switch Group ◽  
Relevant Outcome

Background: Disease-modifying therapies (DMTs) can reduce the risk of disability worsening in patients with relapsing forms of multiple sclerosis (RMS). High-efficacy DMTs can lead to confirmed or sustained disability improvement (CDI and SDI). Objective and Methods: Post hoc analyses of data from the TRANSFORMS, FREEDOMS, and FREEDOMS II trials and their extensions assessed the effects of fingolimod (0.5–1.25 mg/day) on stabilizing or improving disability over ⩽8 years in participants with RMS. CDI and SDI rates were compared between participants initially randomized to fingolimod, interferon (IFNβ-1a), or placebo. Results: At 8 years’ follow-up in TRANSFORMS, 35.1% (95% confidence interval [CI], 28.2%–43.1%) of assessed participants in the IFNβ-1a–fingolimod switch group and 41.9% (36.6%–47.6%) on continuous fingolimod experienced CDI; disability did not worsen in approximately 70%. Similar results were seen in the combined FREEDOMS population. Proportionally fewer TRANSFORMS participants achieved SDI in the IFNβ-1a–fingolimod switch group than on continuous fingolimod (5.4% [3.0%–9.5%] vs 14.2% [10.8%–18.4%], p = 0.01). Conclusion: CDI and SDI are outcomes of interest for clinical trials and for long-term follow-up of participants with RMS. Monitoring CDI and SDI in addition to disability worsening may facilitate understanding of the therapeutic benefit of RMS treatments.

scholarly journals Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

1978 ◽  
Vol 5 (2) ◽  
pp. 175-178 ◽  
Author(s):  
L.F. Kastrukoff ◽  
D.R. McLean ◽  
T.A. McPherson
Keyword(s):  
Multiple Sclerosis ◽  
Total Protein ◽  
Antithymocyte Globulin ◽  
Gamma Globulin ◽  
Multiple Sclerosis Patients ◽  
Term Benefit

SUMMARY:Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.

Sign in / Sign up

Export Citation Format

Share Document